CTOR Revenue Breakdown
CITIUS ONCOLOGY, INC. (CTOR). Quarter ended 2026-06-30 · 10-Q · every retained filed quarter remains available.
- 2026-06-30: Others Not split by product$1.49M100.00%; Total revenue $1.49M.
- 2026-03-31: Others Not split by product$1.67M100.00%; Total revenue $1.67M.
- 2025-12-31: Others Not split by product$3.94M100.00%; Total revenue $3.94M.
Revenue by product
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $1.49M 100.00% | $1.49M |
| 2026-03-31 | Not split by product $1.67M 100.00% | $1.67M |
| 2025-12-31 | Not split by product $3.94M 100.00% | $3.94M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |